Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET

Company Participants

Alex Braun - Head of Investor Relations
Dan O’Connell - Chief Executive Officer
Matt Zuga - Chief Financial Officer, Chief Business Officer
Dr. Jim Doherty - President, Chief Development Officer
Dr. Eric Siemers - Chief Medical Officer.

Conference Call Participants

Mark Hitrik - Stifel
Tom Shrader - BTIG
Cameron Bozdog - BofA Securities
Samantha Schaeffer - Cantor Fitzgerald

Operator

Hello, and welcome to Acumen Pharmaceuticals Q3 2024 Conference Call and Webcast. [Operator Instructions] I would now like to hand the conference over to Alex Braun. You may begin.

Alex Braun

Thanks, Tawanda. Good morning, and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended September 30, 2024. With me today are Dan O’Connell, our CEO; and Matt Zuga, our CFO and Chief Business Officer. Dan and Matt have some prepared remarks, and then we’ll open the call for questions. Joining for the Q&A session, we also have Dr. Jim Doherty, our President and Chief Development Officer; and Dr. Eric Siemers, our Chief Medical Officer.

Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find a press release issued this morning that we’ll discuss today. Please note that during today’s conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Please see Slide 2 of our corporate presentation, our press release issued this morning and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information, or future results or development.

So with that, I’ll turn the call over to Dan.

Dan O’Connell

Thanks, Alex. Good morning, everyone, and thanks for joining us today. The third quarter was one of focused execution as we continue to progress our clinical efforts for sabirnetug, our next-generation A beta oligomer-targeted antibody for the treatment of early Alzheimer’s disease. ALTITUDE-AD, our Phase II study designed to evaluate the clinical efficacy and safety of sabirnetug in roughly 540 patients with mild cognitive impairment or mild dementia due to Alzheimer’s currently has more than 75 sites active and enrolling across North America, the U.K. and the EU.